Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CELZ is testing lower lows and will not bounce very far. Chart looks terrible!
The CEO says lots of things that never come true while he makes thousands of dollars. The company continues to take out more loans at high interest rates to pay their salaries! This will be sub penny again in 6 months IMO.
A 16% drop is a solid day if you like downward trends!
It is a waving white flag pattern! LOL
There is support in the .02's, so I might take a position when it bottoms out.
Half a Billion Shares dumped since last year! 10Q
Nobody got a rise out of the 10Q either.
Paid in Full = Dilution
500 million increase over last year!
See 10Q
https://ih.advfn.com/p.php?pid=nmona&article=78073050
Waiting for the bottom to play the bounce. I am now a bottom feeder for shit stocks like CELZ!
The golden cross is a bullish breakout pattern formed from a crossover involving a security's short-term moving average breaking above its long-term moving average or resistance level.
In CELZ case, it was weakened by a lack of buying volume and MM manipulation. Thus, the GC of last week was nothing but a bump in the downward trend.
Golden Cross happened last week and stock tanked further. Go figure! Will test .02 support by end of week.
10Q Alert - Going Concern and Management’s Plans
The Company has realized a cumulative net loss of $3,121,555 for the period from inception (June 2, 2015) to June 30, 2018, has
negative working capital of $2,395,226, and no revenues. The Company has insufficient revenue and capital commitments to fund the development of its planned products and to pay operating expenses. These conditions, among others, raise substantial doubt about the Company’s ability to continue as a going concern for a year following the issuance of these condensed consolidated financial statements.
They continue to spend money they don't have and keep placing more debt on shareholders. This is the worst 10Q in the history of the company. The Company is now on a month to month basis under the terms of the office lease.
Just calling CELZ as I see it and I have been spot on the last two weeks. This will test .02 this week! Mark this post!
RIP CELZ! Testing .02 by EOW.
What happened to the Golden Cross hype? If this breaks .03, it will probably test support in the low .02's.
All they have is a part-time CEO blowing cheese!
No revenues, No Sales, No CHS contracts, No NDSU agreement, just more of the same BS fluff crap posted on FB or Blog.
The pps is in the $.03's as predicted!
Fat Chance = $.03's
Excellent post Hornet Driver! Folks need to understand how convertibles devastate these pink OTC scams.
Golden Cross X = CELZ patients peeing in the wind hoping they cross swords! LOL
CELZ only promises more toxic dilution! Avoid Scams
CELZ Bone marrow Stem Cell Scam for ED! No FDA approval here!
https://www.healthline.com/health-news/erectile-dysfunction-stem-cell-treatments-beware-of-scams
Erectile Dysfunction Stem Cell Treatments Emerging — But Beware of Scams
Danish researchers say a new stem cell treatment was effective in treating erectile dysfunction, but experts say the study was flawed. They also warn against ED scams.
https://www.nytimes.com/2017/08/28/health/fda-stem-cell.html
Stem cells, which can be extracted from bone marrow, blood or fat, can develop into many different types of cells, and are thought to have the potential to repair or replace tissue damaged by disease, injury or aging. But so far, the F.D.A. has approved only a few stem-cell products.
Gagged IR, Gagged TA, Sounds like penny scam!
CELZ has a Wedgie for sure! MM's have a tight hold and won't let go!
CMTH/CELZ Been trending down for last two months!
Volume tells it all, no current interest in this stock to move anywhere but down. MM's have full control now.
T-I-M-B-E-R $.03'S COMING SOON!!!
NO CHS REVENUE IN 2018! JUST MORE DILUTION
Buyer Beware!!!
If you adjust the current pps and OS to pre-split numbers it sure resembles a company with massive dilution going nowhere!
Current PPS $0.06 / 300 = $0.0002
Current OS 67.5 million X 300 = 20.25 Billion shares
LOL. If you read the article it says the procedure does not make it bigger!
Thanks! That explains why bone marrow is not FDA regulated for their Creative ED treatment.
Bone Marrow may be the way they skate past FDA approvals. Scroll to the bottom section.
Is cmth/celz on shakey ground?
https://www.fda.gov/forconsumers/consumerupdates/ucm286155.htm
FDA Warns About Stem Cell Therapies
Researchers hope stem cells will one day be effective in the treatment of many medical conditions and diseases. But unproven stem cell treatments can be unsafe—so get all of the facts if you’re considering any treatment.
Red envelope icon Subscribe: FDA Consumer Health Information
Stem cells have been called everything from cure-alls to miracle treatments. But don’t believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware of potentially dangerous procedures—and confirm what’s really being offered before you consider any treatment.
The facts: Stem cell therapies may offer the potential to treat diseases or conditions for which few treatments exist. Sometimes called the body’s “master cells,” stem cells are the cells that develop into blood, brain, bones, and all of the body’s organs. They have the potential to repair, restore, replace, and regenerate cells, and could possibly be used to treat many medical conditions and diseases.
But the U.S. Food and Drug Administration is concerned that some patients seeking cures and remedies are vulnerable to stem cell treatments that are illegal and potentially harmful. And the FDA is increasing its oversight and enforcement to protect people from dishonest and unscrupulous stem cell clinics, while continuing to encourage innovation so that the medical industry can properly harness the potential of stem cell products.
To do your part to stay safe, make sure that any stem cell treatment you are considering is either:
•FDA-approved, or;
•Being studied under an Investigational New Drug Application (IND), which is a clinical investigation plan submitted and allowed to proceed by the FDA.
And see the boxed section below for more advice.
Stem Cell Uses and FDA Regulation
The FDA has the authority to regulate stem cell products in the United States.
Today, doctors routinely use stem cells that come from bone marrow or blood in transplant procedures to treat patients with cancer and disorders of the blood and immune system.
With limited exceptions, investigational products must also go through a thorough FDA review process as investigators prepare to determine the safety and effectiveness of products in well-controlled human studies, called clinical trials. The FDA has reviewed many stem cell products for use in these studies.
As part of the FDA’s review, investigators must show how each product will be manufactured so the FDA can make sure appropriate steps are being taken to help assure the product’s safety, purity, and strength (potency). The FDA also requires sufficient data from animal studies to help evaluate any potential risks associated with product use. (You can learn more about clinical trials on the FDA’s website.)
That said, some clinics may inappropriately advertise stem cell clinical trials without submitting an IND. Some clinics also may falsely advertise that FDA review and approval of the stem cell therapy is unnecessary. But when clinical trials are not conducted under an IND, it means that the FDA has not reviewed the experimental therapy to help make sure it is reasonably safe. So be cautious about these treatments.
About FDA-approved products derived from stem cells
The only stem cell-based products that are FDA-approved for use in the United States consist of blood-forming stem cells (hematopoietic progenitor cells) derived from cord blood.
These products are approved for limited use in patients with disorders that affect the body system that is involved in the production of blood (called the “hematopoietic” system). These FDA-approved stem cell products are listed on the FDA website. Bone marrow also is used for these treatments but is generally not regulated by the FDA for this use.
Safety Concerns for Unproven Stem Cell Treatments
All medical treatments have benefits and risks. But unproven stem cell therapies can be particularly unsafe.
For instance, attendees at a 2016 FDA public workshop discussed several cases of severe adverse events. One patient became blind due to an injection of stem cells into the eye. Another patient received a spinal cord injection that caused the growth of a spinal tumor.
Other potential safety concerns for unproven treatments include:
•Administration site reactions,
•The ability of cells to move from placement sites and change into inappropriate cell types or multiply,
•Failure of cells to work as expected, and
•The growth of tumors.
Note: Even if stem cells are your own cells, there are still safety risks such as those noted above. In addition, if cells are manipulated after removal, there is a risk of contamination of the cells.
FDA Actions on Unapproved Stem Cell Products
When stem cell products are used in unapproved ways—or when they are processed in ways that are more than minimally manipulated, which relates to the nature and degree of processing—the FDA may take (and has already taken) a variety of administrative and judicial actions, including criminal enforcement, depending on the violations involved.
In August 2017, the FDA announced increased enforcement of regulations and oversight of stem cell clinics. To learn more, see the statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA website.
And in March 2017, to further clarify the benefits and risks of stem cell therapy, the FDA published a perspective article in the New England Journal of Medicine.
The FDA will continue to help with the development and licensing of new stem cell therapies where the scientific evidence supports the product’s safety and effectiveness.
Advice for People Considering Stem Cell Therapies
Stem cell products have the potential to treat many medical conditions and diseases. But for almost all of these products, it is not yet known whether the product has any benefit—or if the product is safe to use.
If you're considering treatment in the United States:
•Ask if the FDA has reviewed the treatment. Ask your health care provider to confirm this information. You also can ask the clinical investigator to give you the FDA-issued Investigational New Drug Application number and the chance to review the FDA communication acknowledging the IND. Ask for this information before getting treatment—even if the stem cells are your own.
•Request the facts and ask questions if you don’t understand. To participate in a clinical trial that requires an IND application, you must sign a consent form that explains the experimental procedure. The consent form also identifies the Institutional Review Board (IRB) that assures the protection of the rights and welfare of human subjects. Make sure you understand the entire process and known risks before you sign. You also can ask the study sponsor for the clinical investigator’s brochure, which includes a short description of the product and information about its safety and effectiveness.
If you're considering treatment in another country:
•Learn about regulations that cover products in that country.
•Know that the FDA does not have oversight of treatments done in other countries. The FDA typically has little information about foreign establishments or their stem cell products.
•Be cautious. If you’re considering a stem cell-based product in a country that may not require regulatory review of clinical studies, it may be hard to know if the experimental treatment is reasonably safe.
Updated: November 16, 2017
Wanning interest in CELZ, dropping into $.03's soon!
Lack of power hour!
Trading volume tells us there is not interest in this stock!
Mid $.03's is my guess. No buying pressure like before!
I will keep on my watch list for now. Good luck!
Why not sell and buy back lower later after they short!
April - June was the pump! July - August the dump!
Hornet, I'm not touching this stock with a 10 inch pole!
Thanks for your DD man!
Bone marrow boners! Is that their new slogan?
I am sure that will get a rise out of investors!
Have a good weekend everyone!
Forward looking statements are not facts! TIMBER!
Can you share a link? Thx
Creative Medical is pathetic! Can't hold gains when the company has no cash and keeps diluting. Good luck!
$7.5 million Net Loss! No Cash! Dilution!
It's all explained here.
https://ih.advfn.com/p.php?pid=nmona&article=78002766